Search Results

Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine System ™ Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months.

Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million.

Biocytogen Pharmaceuticals and ABL Bio Inc. today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).

Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the completion of patient enrollment in the TARGET BP I Pivotal Study evaluating alcohol-mediated renal denervation with the Peregrine System.

UL Solutions Inc. (“UL Solutions” or the “Company”) (NYSE: ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the first quarter ended March 31, 2024.

Acclaro Medical, a medical technology company that specializes in developing and delivering trailblazing solutions for medical aesthetics and surgical practitioners worldwide, today announced clearance by the U.S. Food and Drug Administration (FDA) for a new indication of the Company’s UltraClear® cold ablative fractional 2910 nm fiber laser.